1.
Bavelloni A, Piazzi M, Ramazzotti G, Fiume R, Blalock W, Faenza I. PI3Kα-selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma. Ital J Anat Embryol [Internet]. 2017 Oct. 6 [cited 2024 May 1];122(1):21. Available from: https://oajournals.fupress.net/index.php/ijae/article/view/1730